No Data
No Data
Overseas revenue plummets, dragging down performance; the fundraising projects of Ota Biotechnology are delayed.
① Due to the impact of international situations, economic policies, and fluctuations in the overall market, the fundraising projects of Aotai Biological aimed at expanding overseas markets will be delayed. ② Overseas revenue has always been the most core source of income for Aotai Biological, with the overall income proportion once reaching 99.83%, and the sharp decline in overseas revenue has also led to a significant drop in Aotai Biological's overall income.
Hangzhou Alltest Biotech Co., Ltd. (SHSE:688606) CEO Fei Gao, the Company's Largest Shareholder Sees 7.7% Reduction in Holdings Value
Aotai Biotech: Third quarter report 2024
Third Quarter Report 2024
Aotec Biology (688606.SH) released its performance for the first three quarters, with net income of 0.198 billion yuan, a year-on-year increase of 94.48%.
Aotec Pharmaceuticals (688606.SH) disclosed the third quarter report for 2024, achieving revenue of 6....
Otaix Biotech (688606.SH): The proposed mid-term profit distribution for 2024 is a dividend of 15 yuan per 10 shares.
On September 19th, GeLongHui (688606.SH) announced the mid-term profit distribution plan for 2024, stating that the company plans to distribute a cash dividend of 15 yuan (including taxes) per 10 shares to all shareholders.
Is Hangzhou Alltest Biotech Co., Ltd.'s (SHSE:688606) Stock Price Struggling As A Result Of Its Mixed Financials?